

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA123; Varenicline for smoking cessation

This guidance was issued July 2007 with a review date of May 2010

Background

At the GE meeting [28 September 2010] it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	<ul style="list-style-type: none">• The guidance should be transferred to the 'static guidance list'.• The NICE Public Health team has received a remit <i>"to update existing NICE Guidance (Technology Appraisals and Public Health Guidance) on technologies used in smoking cessation"</i>. The decision to send the guidance to the static list may need to be reconsidered when this project begins.
------------------------------------	---

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	<ul style="list-style-type: none">• The guidance should be transferred to the 'static guidance list'.• The decision to send the guidance to the static list will be reconsidered when work on the project <i>"to update existing NICE Guidance (Technology Appraisals and Public Health Guidance) on technologies used in smoking cessation"</i> begins.
--	---

Respondent	Response to proposal	Details	Comment from Technology Appraisal
British Cardiovascular Intervention Society	No comment		No action required.
Heart Care Partnership (UK)	Agree		Comment noted. No action required.
Pfizer	Agree		Comment noted. No action required.
NHS Quality Improvement Scotland	No comment		No action required.
Royal College of Physicians	Agree		Comment noted. No action required.
Welsh Assembly Government	No comment		No action required.

No response received from:

<u>Patient/carer groups</u>	<u>General</u>
<ul style="list-style-type: none"> • Action Heart • Afiya Trust • Black Health Agency • Blood Pressure Association • British Cardiac Patients Association • Cancer Black Care • Cancer Equality • Cancer Laryngectomee Trust • Cancer52 • CANCERactive • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Get A-Head 	<ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium

- Helen Rollason Heal Cancer Charity
- Let's Face It
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie Cancer Care
- Mouth Cancer Foundation
- Muslim Council of Britain
- Muslim Health Network
- National Association Of Laryngectomee Clubs
- Network of Sikh Organisations
- Ochre
- Oesophageal Patients Association
- Rarer Cancers Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus

Professional groups

- Association of Cancer Physicians
- British Association for Nursing in Cardiac Care
- British Association for Services to the Elderly
- British Association of Emergency Medicine
- British Atherosclerosis Society
- British Cardiovascular Society
- British Geriatrics Society
- British Heart Foundation
- British Nuclear Cardiology Society
- British Oncological Association (BOA)
- British Psychosocial Oncology Society
- British Society of Cardiac Radiology

Comparator manufacturers

- GlaxoSmithKline Consumer Healthcare (nicotine replacement therapy)
- GlaxoSmithKline UK (bupropion)
- McNeil Products (nicotine replacement therapy)
- Novartis Consumer Health UK (nicotine replacement therapy)
- Pfizer (nicotine replacement therapy)
- Pierre Fabre (nicotine replacement therapy)
- Teva UK (nicotine replacement therapy)

Relevant research groups

- British Society for Cardiovascular Research
- Cardiac and Cardiology Research Dept, Barts and The London
- Cardiovascular Diseases Specialist Library
- Cochrane Heart Group
- Cochrane Peripheral Vascular Diseases Group
- CORDA
- European Council for Cardiovascular Research
- Institute of Cancer Research
- MRC CTU
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- Policy Research Institute on Ageing and Ethnicity
- Research Institute for the Care of Older People
- Wellcome Trust

Assessment Group

<ul style="list-style-type: none"> • Cancer Networks Pharmacists Forum • Cancer Research UK • National Heart Forum • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society of Cardiothoracic surgeons • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Plymouth • NHS Redbridge 	<ul style="list-style-type: none"> • Assessment Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None
---	---

GE paper sign-off: Janet Robertson, 15th November 2010

Contributors to this paper:

Technical Lead: Raisa Sidhu
 Technical Adviser: Nicola Hay
 Project Manager: Andrew Harding